Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 9, 2001, Pages 517-522

  Davis, Thomas A ^a   Hsu, Frank J ^a   Caspar, Clemens B ^a   Van Beckhoven, Adrienne ^a   Czerwinski, Debra K ^a   Liles, Tina Marie ^a   Taidi, Behnaz ^a   Benike, Claudia J ^a   Engleman, Edgar G ^a   Levy, Ronald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti Id response; Idiotype vaccination; KLH; Non Hodgkin's lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN IDIOTYPE;

ANTIGEN SPECIFICITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B CELL LYMPHOMA; CANCER RECURRENCE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG MEGADOSE; DRUG TOLERABILITY; ERYTHEMA; EXPERIENCE; FATIGUE; FEVER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MEDICAL DOCUMENTATION; MINIMAL RESIDUAL DISEASE; MYALGIA; NONHODGKIN LYMPHOMA; REMISSION; SURVIVAL RATE; VACCINATION; WHOLE BODY RADIATION;

EID: 0034774902     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11669219     Document Type: Article

References (31)

1. Surface immunoglobulin of B-lymphocytic tumours as a therapeutic target
2. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation
3. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity
4. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
5. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide
6. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial
7. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
8. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
9. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients
10. Immune reconstitution after autologous purged bone marrow transplantation in children
11. Persistent changes in the immune system 4-10 years after ABMT
12. Reimmunization after blood or marrow stem cell transplantation
13. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine
14. Reconstitution of the cellular immune response after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin's lymphoma
15. A phase II study of adjuvant therapy with anti-B4-blocked Ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma
16. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy
17. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: Initial studies in a murine model
18. Syntex adjuvant formulation
19. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
20. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2+ precursors
21. Dendritic cells in the treatment of cancer
22. Dendritic cells: Potential role in cancer therapy
23. Mouse × human heterohybridomas as fusion partners with B cell tumors
24. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma
25. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study
26. A comparison of toxicity and stimulated immune response from adjuvants used in idiotype vaccination of B-cell lymphoma
27. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: Active immunization with tumor-derived idiotypic immunoglobulin
28. Sustaining the graft-versus-tumor effect through posttransplant immunization with GM-CSF-producing tumor vaccines
29. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
30. Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells
31. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy